Ph 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints November 26, 2024
Truqap combination in PTEN-deficient mHSPC demonstrated statistically significant and clinically meaningful improvement in rPFS in CAPItello-281 Ph 3 trial November 26, 2024
Eflornithine and Lomustine Combination Shows Clinically Meaningful Improvements in OS and PFS in Patients with Recurrent Astrocytoma IDH Mutant Grade 3 November 26, 2024
FAILED TRIAL: Topline Data Announced from SELECT-MDS-1 Ph 3 Trial of Tamibarotene in Higher-Risk MDS with RARA Gene Overexpression November 19, 2024
ECLIPSE Trial Meets Primary Endpoint, Showing a Statistically Significant & Clinically Meaningful Benefit for Patients With PSMA+ve metastatic CRPC November 19, 2024
Annamycin + Ara-C achieved 60% CR/CRi in AML patients who were relapsed from or refractory to Venetoclax regimens November 19, 2024
Further positive data announced from SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma November 19, 2024
Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile November 13, 2024
FAILED TRIAL: Ph 2/3 Study of Uproleselan Did Not Meet Primary Endpoint of EFS improvement in elderly 1L AML patients November 5, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented November 5, 2024
Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released November 5, 2024
Highly Significant Results In Ph 3 Study Of Ameluz®-Photodynamic Therapy (PDT) in Superficial Basal Cell Carcinoma (sBCC) Announced November 5, 2024
Positive Interim Ph 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced October 29, 2024
Interim Clinical Proof-of-Concept Data for TYRA-300 in Ph 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) reported October 29, 2024
Updated Safety & Efficacy Data for Ph 1/2 Study of ONCT-534 for Treatment of R/R metastatic CRPC Announced October 29, 2024
